All News

glomerulonephritis.GN_.lupus_.jpg

Belimumab in Lupus Nephritis

d Jack Cush, MD

Belimumab has been studied in an active lupus nephritis, phase 3 trial call BLISS-LN and shown to be effective as measured by  trial of belimumab for the treatment of active lupus nephritis in adult patients.

Read Article
Lupusfoto.jpg

Is Anifrolumab Good Enough for Systemic Lupus Erythematosus?

d Jack Cush, MD

The NEJM published favorable results of a phase 3 trial of the alpha interferon inhibitor, anifrolumab, showing it to be superior to placebo in active systemic lupus erythematosus (SLE) patients studied for 48 weeks.

Read Article
SCLE054.jpg

Fewer Lupus Flares on Low Dose Steroids

d Jack Cush, MD

French researchers have shown that patients with systemic lupus erythematosus (SLE) and inactive disease are less likely to flare while taking a 5 mg prednisone maintenance dose.

Read Article
obesity.back_.jpg

Obesity Not Discussed by Doctors and Patients

d Jack Cush, MD

Reuters -  Doctors rarely talk about weight concerns with patients who are overweight or obese, and when they do, patients’ experiences tend to be negative, according to a new review of research based on interviews.

Read Article
gout.podag1__1.jpg

A Role for SGLT2 Inhibition in Gout?

d RheumNow

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Read Article
exhausted.jpg (keep)

Domestic Abuse Linked to Fibromyalgia and Chronic Fatigue

d Jack Cush, MD

Domestic violence was found to predispose to a higher risk of fibromyalgia and those developing chronic fatigue syndrome.

Read Article
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

No Cancer Risk with Systemic Necrotizing Vasculitis

d Jack Cush, MD

The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.

Read Article
So many new treatments on the horizon: voclosporin, anifrolumab, belimumab for LN. The year of the wolf 🐺 #Lupus https://t.co/uDzIzU0pvK

Links:

Ali Duarte, MD AliDuarteMD ( View Tweet)

Early Lupus study of 230 pts -Assess by SLICC/ACR Damage Index - 22% had Damage Index ≥1 after 12 months, 26% qt 2 yrs and 29%) @ 3 yrs. Risk factors included Dyslipidaemia (HR 2.9), older age (3.0), #organs/systems (1.4), CVresp Dz (1.9) https://t.co/JUrgTN5hII

Links:

Dr. John Cush RheumNow ( View Tweet)

Why are we guessing? A 20 yr #RA pt, Severe, erosive, polyarticular CCP+ RA, failed MTX, SSZ, Enbrel, Humira, Cimzia, Xeljanz, Orencia; had TJC 22, SJC 18, CDAI 37; put on LEF & IL-6 inhib & 2 mos later SJC 2, CDAI 3! HELP! We need a better way! AI #bigdata, #realbiomarkers

Dr. John Cush RheumNow ( View Tweet)

In Southern Sweden, the prevalence of non-gout crystal arthropathy (>1/3 of which was CPPD) is 0.23%, w/ meage of 71 yrs, more in men and increases w/ age. The incidence is 21.5 (19–25) cases/100,000 persons. https://t.co/MLIhxBPUSO

Links:

Dr. John Cush RheumNow ( View Tweet)

Should AS/SpA pts have ECHO for AI/AR? I say YES; Swedish study of 6448 AS pts shows 2 fold higher risk AI https://t.co/lchlsGXAJi. Another ECHO study 187 AS pts shows an incr prevalence (18%) of AI murmur esp w/ longstanding disease or age >50 (>50%) https://t.co/Np21FwCbBP

Links:

Dr. John Cush RheumNow ( View Tweet)

There is a 2 fold higher rate of RE-Vertebral fractures in Primary Osteoporosis patients who had a previous percutaneous vertebroplasty (PVP) and when taking steroids (vs no steroids). https://t.co/rQaqZnmaD5

Links:

Dr. John Cush RheumNow ( View Tweet)

retrospective cohort study of CCP+ individuals without RA, were followed, showing that they were more likely to progress to RA in 5 yrs if they had high CCP antibody levels (46%). (HR 4.83 [95% CI 2.51–9.31]) https://t.co/Vuaqly1M5Y

Links:

Dr. John Cush RheumNow ( View Tweet)

From 2007 to 2018, claims for Lyme disease increased nationally 117%, from 0.027% of all medical claims to 0.058%. Most affected states were New Jersey, Rhode Island, Connecticut, Massachusetts and New York https://t.co/v4XF97O0bU

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective cohort study of 154 RA patients undergoing 244 major surgeries in shows that perioperative use of DMARDs (39%) or biologics (13%) was not associated with 30-day odds of post-operative infection #ACR19 Abst #1805 https://t.co/7poDnUhRNf

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has approved Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily use in moderately to severely active ulcerative colitis (UC), after an inadequate response or intolerance to TNF blockers. https://t.co/L9lcHfosU1

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up - The Elusive Hand OA Problem (12.13.19) Watch it here>> https://t.co/l75xB48JqW or listen to the podcast here >> https://t.co/hLChtsUSdu

Links:

Dr. John Cush RheumNow ( View Tweet)

Great Full Text, Full Read review of obstructive sleep apnea in 12/3/19 Annals of Internal Medicine Mild OSA: AHI or REI ≥5 but <15 events/h Moderate OSA: AHI or REI ≥15 but <30 events/h Severe OSA: AHI or REI ≥30 events/h https://t.co/nwNwejhLCn

Links:

Dr. John Cush RheumNow ( View Tweet)

YET another drug fails in erosive hand OA (EHOA). A phase II trial of an IL-1 inhibitor (lutikizumab) vs PBO given to 110 EHOA pts shows not differences in pain outcomes, despite biologic changes in CRP, IL1, neutrophils in those on the IL-1 inhibitor. https://t.co/i2N4vs0Sjb

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×